The Important Prognostic Value Of Pretreatment Stage In Patients Achieving Pathologic Complete Response After Neoadjuvant Therapy Of Esophageal Cancer

jing yang,zhendong xiao,l tan,z zhou,qiang feng,lei wang,hong zhang,degang chen,jinsheng liang,zhang hui,wensheng yin,jiehua he

DOI: https://doi.org/10.1016/j.ijrobp.2014.05.1144

2014-01-01

Abstract:Purpose/Objective(s): Previous studies have depicted a correlation between 18FDG PET maximum standardized uptake value (SUVmax) and pathologic complete response (pCR) in patients treated with preoperative chemoradiation therapy (CRT) for esophageal cancer. However, it is unclear whether or not this correlation differs based on tumor histology. Our objective is to determine how SUVmax before and after neoadjuvant CRT for esophageal carcinoma relates to the rate of pCR at surgical resection, and to examine whether or not the relationship varies based on histology. Materials/Methods: After IRB approval, patients at two NCI-designated cancer centers from 2000-2013 who were treated with neoadjuvant CRT followed by surgical resection for esophageal cancer were identified. Medical records were reviewed to gather clinical, radiographic, and pathologic data. PET scans were performed prior to and 3-6 weeks after the completion of preoperative CRT. SUVmax was measured at each scan, and the percent decrease in SUVmax was calculated. A least squares regression analysis was performed to investigate an association between pCR and important clinical factors. Results: One hundred and thirty-two patients were identified. Median age was 62 (36-80), 79% male and 21% female. Adenocarcinoma was identified in 83% and squamous cell carcinoma in 16%; one patient had a neuroendocrine tumor. One hundred and four (79%) patients had a PET scan both prior to and after the completion of preoperative CRT. Thirty percent of patients achieved a pCR, 20% had residual microscopic disease, and 50% had gross residual disease. The pCR rates for adenocarcinoma and squamous cell carcinoma were 28% and 36% respectively. The percent decrease in SUVmax was significantly associated with pCR (p Z 0.04). The median preand post-treatment SUVmax were 9.5 (2.3 44.4) and 4.1 (0 24.4) respectively, and did not differ significantly based on histology. The mean reduction in SUVmax was 60%. For patients achieving a pCR, the mean reduction was 69% compared to 56% for patients with residual disease. When controlling for histology, SUVmax remained associated with pCR (p Z 0.04). The median post-treatment SUVmax was 4.1. Patients who had a post-treatment SUV of 4.1 or less were more likely to have a pCR (p Z 0.02). Conclusions: In this cohort of patients, we confirm that SUV response after neoadjuvant CRT is significantly associated with pCR. Additionally, this association holds true when controlling for histologic type. These data should be considered as new approaches are modeled based on responseadapted therapy. Author Disclosure: M. Zaki: None. T. Shaikh: None. M. Dominello: None. E.J. McSpadden: None. M. Yu: None. S. Cohen: None. W. Scott: None. A. Shields: None. P. Philip: None. M. Choi: None. J.E. Meyer: None. A.A. Konski: None.